Zidovudine paediatric formulation - Mylan Laboratories
Latest Information Update: 20 Apr 2015
At a glance
- Originator Matrix Laboratories
- Developer Mylan Laboratories Limited
- Class Antiretrovirals; Azides; Nucleosides; Small molecules
- Mechanism of Action Nucleoside reverse transcriptase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Marketed HIV infections
Most Recent Events
- 15 Mar 2016 Biomarkers information updated
- 19 Oct 2011 Matrix Laboratories is now called Mylan Laboratories Inc.
- 10 Mar 2011 Registered for HIV infections (prevention of mother-to-child transmission) in USA (PO)